Cosmetics Sector Growth Continues, Autoimmune Drug Results in Focus

In particular, brands such as Estra have gained popularity in Europe, and steady growth across brands has begun to be observed. In addition, the continued expansion of offline channels such as Sephora is having a positive effect on market scalability.

For cosmetics stocks, the current market mood is not bad, so a strategy of adding exposure at this stage to lower the average cost and realize profits quickly is viewed positively. However, a process of absorbing the supply zone within the ₩150,000 to ₩170,000 range appears necessary. If exposure is reduced during this process, a strategy of holding some shares for the long term can be considered.

The viewer bought Hanol Bio Pharma at ₩59,715 with 100% exposure and is still holding it. Market expectations linked to Immunovant are high, but actual results in the autoimmune drug segment are identified as the key factor that will determine investor sentiment. In particular, some noise has arisen in connection with the Chinese company Harbour BioMed, and issues regarding the patent principle are also being raised, so caution is needed.

Therefore, once it moves past ₩70,000, partially selling about 30% of the total holdings to reduce exposure is recommended. The remaining shares can be held while watching for elastic price movement.

In particular, it is collaborating with POSCO E&C to carry out large-scale overseas projects in Thailand and several other countries. This project momentum from overseas bases in Southeast Asia and elsewhere serves as an important basis for holding the stock.

For viewers, a breakout above ₩58,000 is the first hurdle, and beyond that, another resistance is expected in the ₩65,000 range. The ₩57,000 level is currently acting as both key resistance and support, with first target price set at ₩58,000 and second at ₩65,000. If it fails to break above ₩65,000, switching stocks is recommended.

The viewer bought SEMIFIVE at ₩18,811 with 60% exposure. As Samsung Foundry's utilization rate rises, the company is expected to benefit and its earnings are likely to turn around. Its current order backlog is about ₩120 billion, and if accompanied by trading volume, a move close to the ₩20,000 range can be expected.

SEMIFIVE's current share price is considered one of its important support zones, so the likelihood of a sharp decline is low. If it falls back to the ₩13,000 range, this may be a temporary drop caused by stop-loss selling, and it is advised to treat that point as an opportunity to add shares. However, at the current price level, a strategy of monitoring the trend is needed rather than aggressively adding exposure.

The viewer bought Mobis at ₩5,600 with 17% exposure. Mobis has tended to move mainly when fusion-related momentum or superconductor-related issues emerge. In other words, it shows a pattern of heightened volatility in response to specific thematic news.

Mobis is currently out of step with the market's leading trend, and sustained upward movement requires clear momentum. Therefore, rather than adding exposure, reducing it is recommended. If the stock is held, investors must be prepared for a long-term response, so it may be more efficient to cut exposure and look for other opportunities.

Mobis has a market capitalization of less than ₩100 billion, so it can show large volatility. The first target price is set at ₩4,000, and going higher would require backing from new major catalysts. For now, it is judged that a initial rise to around ₩4,000 is likely.

SK IE Technology is a manufacturer of lithium-ion battery separators, and it currently lacks momentum in terms of earnings. Based on the earnings it shows, it is difficult to give a positive assessment. It appears to be stalled due to delayed results at SK On and other group companies.

Expectations for a rebound in the secondary battery sector in the second half remain valid, but given SK IE Technology's current weak earnings, the timing of any sale should be considered carefully. If the ₩15,000 to ₩16,000 resistance zone is broken, it could attempt the ₩20,000 range; as it approaches ₩20,000, the advice is to exit and switch into a stock with substance, rather than one with a large loss or relying only on expectations, which may offer faster returns.